Skip to main navigation Skip to search Skip to main content

Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center

  • Joshua D. Hartzell
  • , Robert Neff
  • , Julie Ake
  • , Robin Howard
  • , Stephen Olson
  • , Kristopher Paolino
  • , Mark Vishnepolsky
  • , Amy Weintrob
  • , Gienn Wortmann

Research output: Contribution to journalArticlepeer-review

322 Scopus citations

Abstract

The incidence of acute renal failure, defined by the risk, injury, or failure criteria of the RIFLE criteria (risk, injury, failure, loss, and end-stage kidney disease), in 66 patients who received colistimethate sodium was 45%, and 21% of patients stopped therapy because of nephrotoxicity. The RIFLE criteria should be used in the future to allow for comparison of nephrotoxicity among studies.

Original languageEnglish
Pages (from-to)1724-1728
Number of pages5
JournalClinical Infectious Diseases
Volume48
Issue number12
DOIs
StatePublished - 15 Jun 2009
Externally publishedYes

Fingerprint

Dive into the research topics of 'Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center'. Together they form a unique fingerprint.

Cite this